Quick Answer
Kymera Therapeutics, Inc. reported Earnings Per Share Diluted of $3.69 (loss) per share for the year ending 2025.
- Kymera Therapeutics, Inc. showed a decrease of -23.8% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Kymera Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $0.55 (loss) per share | Q3 2021: $0.56 (loss) per share | Q1 2022: $0.71 (loss) per share | Q2 2022: $0.78 (loss) per share | Q3 2022: $0.79 (loss) per share | Q1 2023: $0.70 (loss) per share | Q2 2023: $0.67 (loss) per share | Q3 2023: $0.90 (loss) per share | Q1 2024: $0.69 (loss) per share | Q2 2024: $0.58 (loss) per share | Q3 2024: $0.82 (loss) per share | Q1 2025: $0.82 (loss) per share | Q2 2025: $0.95 (loss) per share | Q3 2025: $0.94 (loss) per share.
- Over the full 6 years of available data (2020 to 2025), Kymera Therapeutics, Inc.'s Earnings Per Share Diluted has declined by 17.1%.
- Historical annual values: Fiscal year 2025: $3.69 (loss) per share | Fiscal year 2024: $2.98 (loss) per share | Fiscal year 2023: $2.52 (loss) per share | Fiscal year 2022: $2.87 (loss) per share | Fiscal year 2021: $2.09 (loss) per share | Fiscal year 2020: $3.15 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: